Drug Pipeline

Liposome-encapsulated Daunorubicin-Cytarabine Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
19
Active Studies
11
Recruiting
2
Phase 3
10
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-03 NCT04128748
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of…		 overall status: "Recruiting" → "Active Not Recruiting"
Active Studies by Phase
Phase 3
1
Phase 2/3
1
Phase 2
9
Phase 1/2
3
Phase 1
5
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT04293562 A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for… Acute Myeloid Leukemia Recruiting
Phase 2/3
NCT04217278 A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS… Acute Myeloid Leukaemia Active, Not Recruiting
Phase 2
NCT03629171 Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants… Recurrent Acute Myeloid Leukemia Recruiting
NCT04493164 CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or… Acute Myeloid Leukemia With Gene Mutations Recruiting
NCT05554406 Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With… Acute Myeloid Leukemia Recruiting
NCT05564390 MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study… Acute Myeloid Leukemia Recruiting
NCT05656248 Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms Myeloid Neoplasm Active, Not Recruiting
NCT04231851 CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related… Acute Myelogenous Leukemia (AML) Due to Therapy Active, Not Recruiting
NCT05554419 Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute… Acute Myeloid Leukemia Not Yet Recruiting
NCT04195945 CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade… Acute Myeloid Leukemia Active, Not Recruiting
NCT03672539 Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating… Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Active, Not Recruiting
Phase 1/2
NCT04990102 Phase IB/II of CPX-351 for Relapse Prevention in AML Acute Myeloid Leukemia (AML) in Remission Recruiting
NCT04049539 Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent… Blasts More Than 5 Percent of Bone Marrow Nucleated Cells Recruiting
NCT04128748 Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of… Acute Myeloid Leukemia Active, Not Recruiting
Phase 1
NCT03826992 Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory… Leukemia Recruiting
NCT05558124 CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML Acute Myeloid Leukemia Recruiting
NCT05627232 Tazemetostat and Palbociclib With CPX-351for R/R AML Recurrent Acute Myeloid Leukemia Recruiting
NCT03896269 CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic… Blasts 10-19 Percent of Bone Marrow Nucleated Cells Recruiting
NCT03572764 CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic… Myelodysplastic Syndromes Active, Not Recruiting
Sponsors Running Liposome-encapsulated Daunorubicin-Cytarabine Trials
M.D. Anderson Cancer Center (5) National Cancer Institute (NCI) (3) Washington University School of Medicine (1) Children's Hospital Medical Center, Cincinnati (1) Ohio State University Comprehensive Cancer Center (1) Fred Hutchinson Cancer Center (1) University of Birmingham (1) University of California, Irvine (1) Children's Oncology Group (1) Georgetown University (1)
Disease Areas
Leukemia (17) Acute Myeloid Leukemia (AML) (15) Myelodysplastic Syndromes (MDS) (9) Myelofibrosis (4)
Get alerts when Liposome-encapsulated Daunorubicin-Cytarabine trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free